Poolbeg Pharma (POLB) RNS Announcements

Add to Alert list
Date Time Source Announcement
22 Feb 2024 07:00 AM
RNS
Director/PDMR Shareholding
19 Feb 2024 01:42 PM
RNS
Director Share Purchase
15 Feb 2024 07:00 AM
RNS
Board Role Change and Launch of EIP
12 Feb 2024 07:00 AM
RNS
Market Opportunity for POLB 001 for CRS
17 Jan 2024 07:00 AM
RNS
Further data shows POLB001 potential in cancer CRS
20 Dec 2023 07:00 AM
RNS
RSV AI Drug Candidate Analysis Update
11 Dec 2023 07:00 AM
RNS
POLB 001 Data Presented at ASH
30 Nov 2023 07:00 AM
RNS
Directorate Change
21 Nov 2023 07:00 AM
RNS
Immunomodulator II patent granted in Japan
16 Nov 2023 07:00 AM
RNS
POLB 001 LPS Trial Data to be Presented at IUIS
09 Nov 2023 07:00 AM
RNS
Former Amryt Pharma Leadership Team join Poolbeg
03 Nov 2023 07:05 AM
RNS
POLB001 Data to be Presented at ASH Annual Meeting
01 Nov 2023 07:00 AM
RNS
POLB 001 Oncology Programme Update Meeting
26 Oct 2023 07:00 AM
RNS
SAB Endorses Influenza Drug Targets
17 Oct 2023 07:00 AM
RNS
Poolbeg Partners with a Nasdaq-Listed Biopharma
29 Sep 2023 07:00 AM
RNS
Favourable Conclusion of Patent Opposition
20 Sep 2023 07:00 AM
RNS
Immunomodulator I Patent Portfolio Strengthened
19 Sep 2023 07:00 AM
RNS
Immunomodulator I Patent Opposition Withdrawal
13 Sep 2023 07:00 AM
RNS
Interim results for the six months to 30 June 2023
29 Jun 2023 07:00 AM
RNS
AI led programme identifies influenza drug targets
22 Jun 2023 07:00 AM
RNS
Oral Vaccine Programme Moves Forward
24 May 2023 07:00 AM
RNS
Board Appointment
11 May 2023 02:27 PM
RNS
Results of Annual General Meeting
12 Apr 2023 07:00 AM
RNS
Annual Report & AGM Notice
30 Mar 2023 07:00 AM
RNS
Results for the year ended 31 December 2022
10 Mar 2023 07:00 AM
RNS
Notification of Major Holdings
09 Mar 2023 03:51 PM
RNS
Notification of Major Holdings
08 Mar 2023 07:00 AM
RNS
POLB 001 patent portfolio strengthened
02 Mar 2023 11:05 AM
RNS
Second Price Monitoring Extn
02 Mar 2023 11:00 AM
RNS
Price Monitoring Extension
02 Mar 2023 07:00 AM
RNS
Positive Results POLB001 LPS Human Challenge Trial
16 Jan 2023 07:00 AM
RNS
Strategic expansion of POLB 001 into oncology
09 Jan 2023 09:05 AM
RNS
Second Price Monitoring Extn
09 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
09 Jan 2023 07:00 AM
RNS
Positive Initial Data Analysis in POLB 001 Trial
22 Dec 2022 10:47 AM
EQS
Poolbeg Pharma identifies new RSV drug candidates
21 Dec 2022 07:00 AM
RNS
Poolbeg identifies novel RSV drug candidates
15 Dec 2022 09:48 AM
EQS
Poolbeg Pharma makes 'interesting addition to e...
14 Dec 2022 07:00 AM
RNS
Metabolic diseases oral delivery licence signed
12 Dec 2022 02:05 PM
RNS
Second Price Monitoring Extn
12 Dec 2022 02:00 PM
RNS
Price Monitoring Extension
12 Dec 2022 11:59 AM
EQS
Poolbeg Pharma receives initial results from hu...
12 Dec 2022 07:00 AM
RNS
POLB 001 LPS human challenge trial completed
29 Nov 2022 07:00 AM
RNS
Influenza AI model build completed
21 Nov 2022 11:35 AM
EQS
Poolbeg Pharma wins first non-dilutive grant fu...
18 Nov 2022 02:00 PM
RNS
Price Monitoring Extension
17 Nov 2022 02:05 PM
RNS
Second Price Monitoring Extn
17 Nov 2022 02:00 PM
RNS
Price Monitoring Extension
17 Nov 2022 07:00 AM
RNS
Capital Markets Day
15 Nov 2022 10:36 AM
RNS
Poolbeg-led consortium awarded EUR 2.3m grant
UK 100